From January 21 to 22, 2026, BPI 2026 The 11th New Molecule Antibody Drug R&D Forum was grandly held in Chengdu. The forum brought together leading pharmaceutical enterprises, innovative biotech companies, regulatory experts and investment institutions from home and abroad, and carried out in-depth discussions on key topics such as early-stage R&D innovation of ADC/XDC and bi/multi-specific antibodies, CMC process and quality control, and clinical development.

As a quality and safety control solution provider for pharmaceuticals, Huzhou Shenke Biotechnology Co., Ltd. (HZSKBIO®) displayed its core products and services at the event, and delivered a special report Analysis Strategy of Host Cell Protein (HCP) and Its Impact on Endotoxin Detection. With profound technical accumulation and cutting-edge industry insights, the company won extensive attention and praise from peers on site.

The report centered on HCP control, a core link of biopharmaceutical quality control. It systematically expounded the key technical strategies for HCP analysis, introduced the development process of HCP ELISA (including antigen/calibrator selection, polyclonal antibody preparation and characterization), and explored the interference of residual HCP on endotoxin detection. It was found that HCP with serine protease activity would cause enhancement or inhibition interference by affecting the cascade reaction of tachypleus amebocyte lysate (TAL). A comprehensive pyrogen detection solution can be formed by combining recombinant cascade reagent (rCR), monocyte activation test (MAT) reagent and other tools, which can targeted solve inhibition or enhancement interference and provide support for biopharmaceutical quality control.

At the booth, the staff answered users’ questions about product performance, application scenarios and compliance support in detail, gained an in-depth understanding of the latest industry demands, and accumulated valuable information for subsequent technological R&D and service optimization. Huzhou Shenke will continue to focus on technological innovation in the biomedical quality control field, empower the whole process of biopharmaceutical R&D and production with better products and services, and contribute more to the high-quality development of the industry.